Shares are trading at $1.30 slightly over $1.20, the stock’s 50 day moving average and significantly above the 200 day moving average of $0.94. The 50 day moving average went up by +8.13% and the 200 day average was up $0.36. 0 shares changed hands by the end of trading on Wednesday. Volume was down nan% under the stocks average daily volume.
A few notable investment firms have updated their holdings. As of quarter end Wells Fargo & Company/mn had disposed of a total of 4 shares trimming its stake by 1.0%. The value of the total investment in Merus Labs International Inc. decreased from $0 to $0 a change of nan% quarter over quarter. Citadel Advisors LLC augmented its position by buying 3,369 shares an increase of 15.4%. Citadel Advisors LLC now holds 25,195 shares worth $31,000. The total value of its holdings increased 55.0%.
As of the end of the quarter Morgan Stanley had bought 13,600 shares growing its holdings by 36.8%. The value in dollars went from $34,000 to $64,000 increasing 88.2% since the last quarter. As of quarter end Toronto Dominion Bank had bought 1,703 shares growing its position 2,155.7%. The value of the investment in MSLI increased from $0 to $2,000 a change of $2,000 for the reporting period.
Merus Labs International Inc., a specialty pharmaceutical company, engages in the acquisition of prescription medicines primarily in Canada and Europe. The company offers Sintrom, an anti-coagulant drug for the treatment and prevention of thromboembolism diseases; Emselex/Enablex, a prescription medicine for the treatment of urinary urgency and incontinence for adults; and Salagen, an oral tablet for the treatment of symptoms associated with radiation therapy. It also provides Vancocin, a capsule for the treatment of the Clostridium Difficile infection; and Estraderm, a hormone replacement therapy that contains the female hormone estrogen. The company is headquartered in Toronto, Canada..